Mr. Ron Nagar reports

TEMPRAMED SIGNS NON-BINDING LOI WITH NATIONAL DISTRIBUTOR IN SAUDI ARABIA

Tempramed Technologies Ltd. has signed a non-binding letter of intent dated June 16, 2026, with Rawafed Health International Company, a leading health care distribution company with broad reach across pharmacy networks and health care infrastructure in the region. The LOI provides a pathway to entering into an exclusive distribution of Tempramed products in the Kingdom of Saudi Arabia.

The LOI sets out the principal terms under which the parties intend to negotiate and enter into the proposed distribution agreement, which provides for a five-year distribution arrangement within Saudi Arabia, with exclusivity requiring minimum purchase orders from Rawafed of approximately $3.1-million (U.S.) over the five-year period. The LOI contemplates the proposed distribution agreement to include performance review mechanisms, along with Rawafed providing regulatory and market development support; however, there is no guarantee the company and Rawafed will enter into the proposed distribution agreement on the terms contemplated by the LOI or at all.

The proposed distribution agreement initially includes Vivi Cap, with additional Tempramed products potentially added by mutual agreement, including future product formats and smart solutions. Under the LOI, exclusivity would become effective following successful regulatory approval by the Saudi Food and Drug Authority and placement of the first commercial order of at least $170,000 (U.S.). Rawafed plans to commence the process for obtaining regulatory approval for Vivi Cap upon execution of the proposed distribution agreement. Given prior approval of Vivi Cap by the U.S. Food and Drug Administration, the company expects to receive SFDA approval in due course.

Rafawed's marketing plan positions Vivi Cap Smart and related Tempramed products as solutions for medication protection, insulin safety, adherence support and digital health integration in Saudi Arabia's diabetes and injectable medication market.

"Saudi Arabia is one of the most strategically important markets for Tempramed in the Middle East," said Ron Nagar, chief executive officer of Tempramed. "The combination of high temperatures, a large diabetes population, expanding GLP-1 use, and growing demand for biologics and specialty injectables creates a clear need for reliable medication temperature protection.

"Rawafed's local health care experience, pharmacy reach, regulatory capabilities and structured commercialization road map creates a strong strategic partner for introducing Tempramed's medication protection platform into the Saudi market. This LOI represents an important step toward expanding Tempramed's presence in Saudi Arabia and supporting broader growth across the Gulf region."

Saudi Arabia: a strong market for medication temperature protection

Saudi Arabia represents a highly strategic market for Tempramed due to the combination of high chronic disease prevalence, strong projected demand for injectable diabetes and weight management therapies, extreme climate conditions, and increasing regulatory attention to temperature-sensitive pharmaceutical storage and transport.

Independent market and public health sources support this opportunity. The International Diabetes Federation reports that Saudi Arabia had approximately 5.34 million adults with diabetes in 2024, representing 23.1-per-cent adult prevalence, and projects the number of adults with diabetes in Saudi Arabia could reach approximately 9.5 million by 2050. This represents a substantial and growing patient base using insulin and other diabetes therapies that may require temperature protection during daily life, travel, transport and home storage.

In parallel, Saudi Arabia's General Authority for Statistics reported in its 2024 health determinants statistics that 23.1 per cent of individuals aged 15 and above are obese and 45.1 per cent are overweight. These indicators support a growing addressable market for GLP-1 and other injectable therapies used in diabetes and weight management.

Independent market research also indicates strong growth in Saudi Arabia's GLP-1 receptor agonist market, with Grand View Research estimating market revenue of $348.3-million (U.S.) in 2025 and projected growth to $1,248-million (U.S.) by 2033. As use of GLP-1 therapies, biologics, peptides, insulin and specialty injectables expands, Tempramed believes the need for simple, passive, patient-level protection of temperature-sensitive medications will become increasingly important.

The Saudi Food and Drug Authority has published guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products, reflecting the recognized importance of temperature integrity within the health care supply chain. Tempramed's opportunity is complementary to formal supply chain controls: Its products are designed to help protect medication after dispensing, during the patient-controlled phase where medications may be exposed to heat in cars, handbags, outdoor environments, travel, home delivery and daily use.

About Tempramed Technologies Ltd.

Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered thermal insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med. Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time.

We seek Safe Harbor.